- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 2041075-86-7] Atuliflapon
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-122908 |
| Brand: | MCE |
| CAS: | 2041075-86-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 446.50 |
| Molecular Formula | C24H26N6O3 |
| SMILES | O=C([C@H]1[C@H](C(C2=CC=C(C3=NNC(C)=C3)C=C2)=O)CCCC1)NC4=C(N(N=C4)CCN5)C5=O |
Summary
IC50 & Target
IC50: 2 nM (FLAP)
[1]
.
In Vitro
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04734275 | AstraZeneca|Parexel |
Chronic Kidney Disease
|
February 1, 2021 | Phase 1 |
| NCT04492709 | AstraZeneca|Parexel |
Cardiovascular Disease
|
July 30, 2020 | Phase 1 |
| NCT03400488 | AstraZeneca |
Coronary Artery Disease
|
January 16, 2018 | Phase 1 |
| NCT04492722 | AstraZeneca|Parexel|George Clinical Pty Ltd |
Chronic Kidney Disease
|
October 1, 2020 | Phase 2 |
| NCT04210388 | AstraZeneca|Parexel |
Coronary Artery Disease (CAD)
|
January 14, 2020 | Phase 1 |
| NCT03317002 | AstraZeneca |
Coronary Artery Disease
|
October 30, 2017 | Phase 2 |
| NCT05251259 | AstraZeneca |
Asthma
|
January 27, 2022 | Phase 2 |
| NCT02963116 | AstraZeneca |
High Risk Coronary Artery Disease
|
December 20, 2016 | Phase 1 |
| NCT02632526 | AstraZeneca |
Healthy Male Subjects|Cardiovascular Disease
|
February 10, 2016 | Phase 1 |
| NCT04601467 | National University Heart Centre, Singapore|AstraZeneca |
Acute Coronary Syndrome
|
January 1, 2021 | Phase 2 |
| NCT03420092 | AstraZeneca|Parexel |
Coronary Artery Disease
|
February 5, 2018 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 279.96 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL |
| 5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2396 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.